

Criteria for Recognition and Approval of a Novel Pharmacy Residency Program Demonstration Approval Process

Proposal Review Process

For pharmacy residency programs in an area of pharmacy practice for which ASHP has not developed a complete set of competency areas, educational goals, and objectives (CAGOs), organizations must contact the ASHP Accreditation Services Office (ASO) to request a review of a proposal for the recognition of the novel pharmacy residency program.

Requests for recognition of a pharmacy residency program in a novel area of pharmacy practice shall be sent to ASO via email (asd@ashp.org) for an initial review. If the ASO and the ASHP Commission on Credentialing (COC) agree that the request for recognition can proceed to the next level of consideration, ASO will communicate this decision to the organization and the *Criteria for Recognition of a Novel Pharmacy Residency Program Demonstration Approval Process (outlined in b.i.-vi. below)* will be explained and initiated. Organizations will be required to provide the following information for review by the COC:

- a. Formal letter of request describing the purpose of the novel pharmacy residency program, including whether the request is for a PGY1 or PGY2 program type
- b. Describe and provide evidence (references as applicable) the new area of pharmacy practice meets the following novel pharmacy residency program criteria:
 - i. demonstrates that the care of patients and their safety will be improved through recognition of education in that discipline
 - ii. is sufficiently distinct from other ASHP-approved areas of pharmacy practice (e.g., existing PGY1 and PGY2 program types) based on major concepts in medical science and the delivery of patient care
 - iii. represents a new or well-defined field of pharmacy practice not currently represented
 - iv. offers educational content that cannot be incorporated within established residency programs
 - v. will generate sufficient interest and resources to establish the critical mass of quality residency programs with long-term commitment for successful integration of the graduates in the health care system nationally
 - vi. is recognized as the primary pathway to the competent preparation of pharmacists in the new area of pharmacy practice
- c. List of citations to published articles in specialty area/topic and statements/data of need
- d. Proposed program structure
- e. Subject matter/disease state Gap Analysis and a crosswalk of proposed appendices with relevant approved and existing PGY1 or PGY2 programs
- f. Copy of the proposed residency program director Academic and Professional Record (APR) Form

The organization's supporting documentation and proposal for review of a novel pharmacy residency program in a novel area of pharmacy practice must be supplied to the ASO by a deadline set by ASO and will be presented at the next regularly scheduled COC meeting (March or August). The COC's decision will then be reviewed by the ASHP Board of Directors (BOD) at the subsequent ASHP BOD meeting for approval. Following a review by the COC and ASHP BOD of the proposal and associated documents, the organization will be notified of the decision to accept or deny the request for review of a pharmacy residency program in a novel area of pharmacy practice.

Proposals that are accepted will begin a process of collaborating with ASO and identified COC members in the development of a set of program competency areas, educational goals, and educational objectives (CAGOs) and/or appendix (as applicable) specific to this novel pharmacy residency program. Once finalized, the CAGOs (and Appendix as applicable) will be reviewed and considered for approval at the next possible COC meeting (March or August). If the COC approves the CAGOs and/or Appendix, the ASHP Board of Directors (BOD) will review for approval. Following COC and ASHP BOD approvals, the proposing organization will submit an application for accreditation (i.e., pre-candidate; a candidate status application may be submitted if an unaccredited program in the proposed practice area is already in place) along with the residency program director credentials (i.e., current APR), and will now begin the **Novel Pharmacy Residency Program Demonstration** phase. The organization can begin the recruitment process for residents at this time. ASO will publish the approved CAGOs and/or new appendix to existing CAGOs on the ASHP website following ASHP BOD approval.

ASO will guide the program through the Demonstration Program requirements for review and accreditation. The maximum duration of initial accreditation for all Demonstration Pharmacy Residency programs will be no longer than four (4) years. Transition from Demonstration status to a fully approved pharmacy residency program in a novel practice area will not occur until, and if accreditation beyond, the initial period is granted by the COC and a review of required documentation submitted during the demonstration period has been approved.

Sustainability and Relevance of the Novel Pharmacy Residency

The COC will have the right to review and determine the continued viability of any recognized and accredited novel pharmacy residency program on a cyclical basis following an update of the *ASHP Accreditation Standard for Postgraduate Pharmacy Residency Programs* and respective CAGOs (and appendix as applicable) and a review of relevancy to the profession and these set criteria.